fashion -WSS

fashion

author：hotspot 2025-09-30 15:16:57 - browse：7

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Boston competes with Raleigh

WSS

Health Care Service Corp to buy Cigna Medicare Advantage plans

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Data integrity in scientific journals requires "effort" by publishers, institutions

HIV vaccine remains elusive. Immunologists keep trying new ideas

Military medical care influenced by rank and race, new study finds

Wikipedia

fashion

hotspot

Sports medicine is finally prioritizing gender equality

Wearables generate powerful data but its not useful to doctors, yet

Guidelines to prevent youth baseball injuries need more muscle

Second House panel advances two

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Heart attack and stroke risk calculators need revising

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Trump demands the U.S. pay no more for drugs than other countries … again

Arc Institute generative AI designs new CRISPR systems

explore

Boston competes with Raleigh

Merck CEO won’t testify in Senate, citing no expertise in drug prices

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readout LOUD podcast: Live from STAT Breakthrough Summit West

White House pharmacy plagued with problems, investigation finds

When prostate cancer spreads, where it goes matters

focus

entertainment

explore

hotspot